Microperimetry for geographic atrophy secondary to age-related macular degeneration.

age-related macular degeneration anatomic-functional correlation geographic atrophy microperimetry retinal sensitivity visual function

Journal

Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551

Informations de publication

Date de publication:
Historique:
received: 03 07 2018
revised: 15 01 2019
accepted: 17 01 2019
pubmed: 1 2 2019
medline: 28 12 2019
entrez: 1 2 2019
Statut: ppublish

Résumé

Geographic atrophy (GA) is a progressive, advanced form of age-related macular degeneration leading to visual function impairment and irreversible vision loss. Standard clinical tests to evaluate visual function in patients with GA provide poor anatomic-functional correlation, whereas fundus imaging does not assess the visual function deficit. Microperimetry is a psychophysical visual function test that spatially maps retinal sensitivity and allows for identification of correlation of anatomic features with visual function. In this review, we present an overview of mesopic microperimetry for GA, including commercially available microperimetry devices, strategies to capture a mesopic microperimetry test, and strategies to assess and interpret microperimetry data in patients with GA. We demonstrate the importance of microperimetry data for assessing GA progression and for evaluating visual function loss through anatomic-functional correlations. Although valuable, current microperimetry tests require an extensive time commitment from the patient and examiner, and the development of faster, more reproducible and accessible methods is important to enable broader use of microperimetry in both clinical and research settings.

Identifiants

pubmed: 30703401
pii: S0039-6257(18)30157-7
doi: 10.1016/j.survophthal.2019.01.014
pmc: PMC6532786
mid: NIHMS1029605
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-364

Subventions

Organisme : NEI NIH HHS
ID : R01 EY009076
Pays : United States

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Ophthalmology. 2007 Feb;114(2):271-7
pubmed: 17270676
Am J Ophthalmol. 2013 Dec;156(6):1184-1191.e2
pubmed: 23972310
Surv Ophthalmol. 2018 Jan - Feb;63(1):40-55
pubmed: 28579549
Br J Ophthalmol. 2014 Aug;98(8):1050-5
pubmed: 24711655
Ophthalmic Res. 2014;52(2):53-9
pubmed: 24993093
Ophthalmol Retina. 2017 Jan - Feb;1(1):68-76
pubmed: 31047397
Retina. 2013 Mar;33(3):482-9
pubmed: 23400084
Ophthalmology. 2017 Apr;124(4):464-478
pubmed: 28109563
Retina. 2011 Jul-Aug;31(7):1323-31
pubmed: 21540764
Transl Vis Sci Technol. 2016 Nov 15;5(6):6
pubmed: 27867756
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2606-11
pubmed: 25813990
Eye (Lond). 2018 Dec;32(12):1819-1830
pubmed: 30068928
Ophthalmology. 2014 Jul;121(7):1445-52
pubmed: 24629618
Retina. 2015 Sep;35(9):1726-34
pubmed: 25932557
Invest Ophthalmol Vis Sci. 2014 Aug 26;55(10):6431-9
pubmed: 25159206
Invest Ophthalmol Vis Sci. 2012 Nov 09;53(12):7618-24
pubmed: 23074210
Transl Vis Sci Technol. 2017 Jul 13;6(4):7
pubmed: 28713647
BMC Ophthalmol. 2011 Feb 08;11:5
pubmed: 21303544
Asia Pac J Ophthalmol (Phila). 2017 Jan-Feb;6(1):70-79
pubmed: 28161925
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Am J Ophthalmol. 2005 Dec;140(6):1085-93
pubmed: 16376656
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO121-BIO130
pubmed: 28632841
Curr Opin Ophthalmol. 2016 May;27(3):217-23
pubmed: 26866953
Invest Ophthalmol Vis Sci. 2011 Feb 28;52(2):1119-26
pubmed: 20926818
Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):115-21
pubmed: 25515578
Arch Ophthalmol. 2012 Jun;130(6):690-9
pubmed: 22801825
JAMA Ophthalmol. 2015 Apr;133(4):442-8
pubmed: 25632841
Eye (Lond). 1988;2 ( Pt 5):552-77
pubmed: 2476333
Retina. 2016 Oct;36(10):1806-22
pubmed: 27652913
Am J Ophthalmol. 2017 Jul;179:118-128
pubmed: 28385474
Ophthalmology. 2014 Dec;121(12):2415-22
pubmed: 25109931
Invest Ophthalmol Vis Sci. 2013 Jun 26;54(6):4372-84
pubmed: 23696601
Am J Ophthalmol. 2016 Aug;168:260-268
pubmed: 27296489
JAMA Ophthalmol. 2018 Jun 1;136(6):666-677
pubmed: 29801123
JAMA Ophthalmol. 2016 Aug 1;134(8):873-9
pubmed: 27253760
Transl Vis Sci Technol. 2016 May 20;5(3):10
pubmed: 27247858
Optom Vis Sci. 2012 Aug;89(8):1182-91
pubmed: 22820474
Optom Vis Sci. 2011 Jul;88(7):881-9
pubmed: 21532519
Br J Ophthalmol. 2013 May;97(5):622-6
pubmed: 23410728
Ophthalmologica. 2017;237(1):42-54
pubmed: 27997924
Invest Ophthalmol Vis Sci. 2013 Nov 11;54(12):7378-85
pubmed: 24135753
Ophthalmology. 2014 Aug;121(8):1612-9
pubmed: 24661863
Ophthalmology. 2014 May;121(5):1079-91
pubmed: 24433969
Am J Ophthalmol. 2016 Aug;168:122-128
pubmed: 27189929
Am J Ophthalmol. 2015 Jul;160(1):85-93.e3
pubmed: 25857680
Retina. 2011 Feb;31(2):371-9
pubmed: 20921927
Ophthalmology. 2011 Apr;118(4):679-86
pubmed: 21035861
Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2137-42
pubmed: 25744333
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO268-BIO276
pubmed: 28973313
Curr Opin Ophthalmol. 2015 May;26(3):149-56
pubmed: 25784112
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Invest Ophthalmol Vis Sci. 2015 Mar 03;56(3):2100-6
pubmed: 25736790
Br J Ophthalmol. 2018 Aug;102(8):1054-1059
pubmed: 29146759
Ophthalmology. 2002 Sep;109(9):1737-44
pubmed: 12208725
Invest Ophthalmol Vis Sci. 2012 Feb 21;53(2):841-52
pubmed: 22247458
Acta Ophthalmol (Copenh). 1975 Jun;53(3):293-310
pubmed: 1174394
Retina. 2014 Feb;34(2):321-9
pubmed: 23842105
Am J Ophthalmol. 2012 Jun;153(6):1110-5
pubmed: 22321805
J Vis Impair Blind. 2008 Oct 1;102(10):600-610
pubmed: 20224750
Retina. 2011 Feb;31(2):364-70
pubmed: 21221051
Can J Ophthalmol. 2013 Oct;48(5):350-7
pubmed: 24093179
Transl Vis Sci Technol. 2015 Jun 30;4(3):13
pubmed: 26175959
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO158-BIO167
pubmed: 28692722
Can J Ophthalmol. 2013 Oct;48(5):358-63
pubmed: 24093180
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3464-72
pubmed: 19324853
Ophthalmology. 2018 Mar;125(3):369-390
pubmed: 29110945
Can J Ophthalmol. 2013 Oct;48(5):386-93
pubmed: 24093185
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO61-BIO67
pubmed: 28475704

Auteurs

Karl G Csaky (KG)

Texas Retina Associates, Dallas, Texas, USA; Retina Foundation of the Southwest, Dallas, Texas, USA. Electronic address: kcsaky@retinafoundation.org.

Praveen J Patel (PJ)

NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom.

Yasir J Sepah (YJ)

Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA.

David G Birch (DG)

Retina Foundation of the Southwest, Dallas, Texas, USA.

Diana V Do (DV)

Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA.

Michael S Ip (MS)

Doheny Eye Institute, Los Angeles, California, USA.

Robyn H Guymer (RH)

Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital; Department of Surgery (Ophthalmology), University of Melbourne, Victoria, Australia.

Chi D Luu (CD)

Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital; Department of Surgery (Ophthalmology), University of Melbourne, Victoria, Australia.

Shamika Gune (S)

Genentech, Inc., South San Francisco, California, USA.

Hugh Lin (H)

Genentech, Inc., South San Francisco, California, USA.

Daniela Ferrara (D)

Genentech, Inc., South San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH